Lasse Leino Appointed Chair of the Board at Solid IO

We are pleased to warmly welcome Dr. Lasse Leino as Chair of theBoard at Solid IO.

‍

Lasse brings nearly 30 years of experience in developing pharmaceutical and biotechnology companies, with a strong track record in translating science-based innovations into clinical and commercial applications.

‍

His background combines deep scientific understanding with broad business expertise. Lasse has previously served as long-time CEO of DelSiTech and co-founded both Laurantis Pharma (now Herantis Pharma) and BioCis Pharma. In addition, he has extensive board experience in science-based startups. Lasse holds a PhD in Biochemistry and serves as Adjunct Professor at the Department of Biotechnology, University of Turku.

‍

“Solid IO’s technology is built on strong immunological insight and a clearly defined clinical need. That combination is exceptionally promising. I look forward to working with the team and supporting the company as it enters its next phase,” Leino says.

‍

At Solid IO, Lasse will focus on supporting strategic development, bridging science and business, and strengthening international partnering efforts.

‍

“Lasse’s experience in connecting research with business is particularly valuable at this stage. He brings perspective and realism as we build clinical evidence and establish collaborations with international partners,” says Noora Hujala, CEO and co-founder of Solid IO.

‍

We’re excited to have Lasse on board to strengthen our team and support our journey toward international market entry.

‍